AstraZeneca expands cancer research facility with new 5000 sq ft addition

Frederick City is set to enhance its life sciences capabilities with the approval of a new addition to AstraZeneca's manufacturing facility, aimed at accelerating cancer research. During a recent community outreach meeting on June 23, 2025, representatives from DPR Construction outlined plans for a 5,000 square-foot expansion that will house advanced laboratory equipment for cancer treatment development.

The proposed addition will be situated between existing buildings and is designed to have minimal impact on the surrounding community. The facility will not increase the number of employees or require additional water or sewer services, ensuring that local resources remain unaffected. The construction will involve relocating existing utilities, including a gas line and stormwater systems, to accommodate the new structure.

Erin Pratt, a construction manager with DPR, emphasized the importance of this project, sharing a personal connection to the cause. "I lost my dad six years ago to cancer," Pratt stated, highlighting her commitment to building facilities that could help find cures for the disease. The new labs will enable faster production of protein vials, significantly reducing the time needed to deliver treatments to patients.

The meeting, while attended by a limited audience, showcased the city's ongoing investment in biomedical technology and its commitment to supporting innovative projects that benefit public health. As Frederick continues to develop its life sciences sector, the community can expect to see more initiatives aimed at improving healthcare outcomes and fostering research advancements.